Descriptors
Classification > W - MEDICINE > WC - COMMUNICABLE DISEASES > WC 536 Human viral hepatitis
WC 536 Human viral hepatitis |
Documents disponibles dans cette catégorie (19)



Extend search on down-posting(s)
Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium / Yvres Horsmans / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
![]()
Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium : Part 1: Literature review and results of a national study [printed text] / Yvres Horsmans, Author ; Nancy Thiry, Author ; Maïté le Polain, Author ; Michael Adler, Author ; Isabelle Colle, Author ; Jean Delwaide, Author ; P. Michielsen, Author ; Hans Orlent, Author ; Pierre Van Damme, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - VI, 111 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 127 C) .
ISSN : D/2010/10.273/24 : 0 .
Study n : 2008-11
Languages : English (eng)
Descriptors: Indexation
2008-11 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis B virus ; Hepatitis B, Chronic ; Interferon-alpha ; R127
Classification
WC 536 Human viral hepatitisContents note: 1 AIMS AND METHODS 5 -- 1.1 AIMS 5 -- 1.2 METHODS 5 -- 1.3 OVERVIEW OF THE REPORT, PART 1 AND PART 2 5 -- 2 NATURAL HISTORY AND EPIDEMIOLOGY 6 -- 2.1 HEPATITIS B: TRANSITION AND NATURAL EVOLUTION 6 -- 2.1.1 Introduction 6 -- 2.1.2 Natural history of infections with the HBV 6 -- 2.1.3 Methods 8 -- 2.1.4 Results 9 -- 2.2 HBV IN BELGIUM AND SURROUNDING COUNTRIES 12 -- 2.2.1 Introduction and search strategy 12 -- 2.2.2 Epidemiology for Belgium, France, Germany and The Netherlands 12 -- 2.2.3 General Conclusion 16 -- 3 TREATMENT 17 -- 3.1 INDICATIONS FOR TREATMENT 17 -- 3.1.1 Treatment goals 17 -- 3.1.2 Definition of response 17 -- 3.1.3 Treatment options 18 -- 3.1.4 Interferon and pegylated interferon 18 -- 3.1.5 Nucleos(t)ide analogues in HBeAg-positive patients 20 -- 3.1.6 Nucleos(t)ide analogues in HBeAg-negative patients 24 -- 3.1.7 Nucleos(t)ide analogues in patients with cirrhosis or advanced fibrosis 25 -- 3.2 RECOMMENDATIONS FOR THE TREATMENT 28 -- 3.2.1 The BASL 2007 recommendations 28 -- 3.2.2 The EASL 2009 recommendations 28 -- 3.2.3 Treatment strategies 29 -- 3.2.4 Management of antiviral resistance to current NA therapy 31 -- 4 SITUATION IN BELGIUM 38 -- 4.1 HISTORY OF REIMBURSEMENT OF ANTIVIRAL DRUGS 38 -- 4.2 THE PROSPECTIVE STUDY 39 -- 4.2.1 Rationale 39 -- 4.2.2 Objectives 40 -- 4.2.3 Ethics and privacy protection 40 -- 4.2.4 Study design and schedule 41 -- 4.3 RESULTS OF THE STUDY 43 -- 4.3.1 Patient characteristics 43 -- 4.3.2 Estimation of the number of patients by disease stage, visiting a medical specialist for chronic HBV infection in Belgium. 46 -- 4.3.3 Conclusion for situation in Belgium 50 -- 4.3.4 Quality of life results 50 -- 4.3.5 Conclusion for quality of life assessment 52 -- 5 REVIEW OF THE COST-EFFECTIVENESS LITERATURE 53 -- 5.1 METHODS 53 -- 5.1.1 Literature search strategy 53 -- 5.1.2 Selection criteria 53 -- 5.1.3 Selection process 54 -- 5.2 OVERVIEW OF THE ECONOMIC EVALUATIONS - TRANSVERSAL 56 -- 5.2.1 Analytical technique 56 -- 5.2.2 Perspective 56 -- 5.2.3 Time horizon and discount rate 56 -- 5.2.4 Population 57 -- 5.2.5 Interventions 57 -- 5.2.6 Outcomes 58 -- 5.2.7 Effectiveness / modelling 61 -- 5.2.8 Costs 64 -- 5.2.9 Results 65 -- 5.3 OVERVIEW OF THE ECONOMIC EVALUATIONS - INDIVIDUAL 67 -- 5.4 GENERAL DISCUSSION AND CONCLUSIONS 70 -- 6 APPENDIXES 72 -- 7 REFERENCES 98 Link for e-copy: https://doi.org/10.57598/R127C Format of e-copy: PDF (934,96 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1909 Copies
Barcode Call number Media type Location Section Status No copy Diagnostic et suivi virologiques des hépatites virales / Service des recommandations et références professionelles / Agence Nationale dAccréditation et dÉvaluation en Santé (ANAES) (2001)
![]()
Diagnostic et suivi virologiques des hépatites virales : (à l'exclusion du dépistage en cas de don de sang, d'organes ou de tissu) [electronic document] / Service des recommandations et références professionelles, Author . - paris [France] : Haute Autorité de Santé (HAS), 2001 . - 12 p.. - (Recommandations pour la pratique clinique) .
Languages : French (fre)
Descriptors: Indexation
Diagnosis ; France ; Hepatitis, Viral, Human
Classification
WC 536 Human viral hepatitisLink for e-copy: http://www.has-sante.fr/portail/upload/docs/application/pdf/Hepatites_virales_re [...] Format of e-copy: Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1255 [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium] / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium] : Part 2 [printed text] / Christoph Schwierz, Author ; Nancy Thiry, Author ; Stefaan Van de Sande, Author ; Mohamed Gamil, Author ; Frederik Nevens, Author ; Isabelle Colle, Author ; Yvres Horsmans, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011. - (KCE Reports. Health Technology Assessment (HTA); 157) .
Study n° 2008-11 HTA Chronic hep B
Languages : English (eng)
Descriptors: Indexation
2008-11 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis B virus ; Hepatitis B, Chronic ; R157
Classification
WC 536 Human viral hepatitisContents note: GLOSSARY 2 -- 1 BACKGROUND AND OBJECTIVES 3 -- 1.1 NATURAL HISTORY AND EPIDEMIOLOGY 3 -- 1.2 TREATMENT 4 -- 1.3 OBJECTIVES AND CONTENT OF THE TWO REPORTS 5 -- 2 METHODS 7 -- 2.1 TARGET POPULATION 7 -- 2.2 MODEL STRUCTURE AND BASIC ASSUMPTIONS 7 -- 2.3 TRANSITION PROBABILITIES 9 -- 2.4 DISEASE MANAGEMENT AND TREATMENT COSTS 12 -- 2.5 UTILITIES 13 -- 2.6 ANTIVIRAL TREATMENT 14 -- 3 RESULTS 16 -- 3.1 MODEL VALIDATION: NATURAL EVOLUTION OF DISEASE WITHIN EUROPEAN -- COHORTS 17 -- 3.2 HEALTH OUTCOMES 18 -- 3.2.1 Life-years gained in the three cohorts 18 -- 3.2.2 Undiscounted life-years gained in DC and HCC 19 -- 3.2.3 Mean tenofovir treatment duration in CHB e+ vs e- cohorts 20 -- 3.3 BASE-CASE COST-UTILITY ANALYSES 20 -- 3.3.1 Overview of the results for the three base-case cohorts 20 -- 3.3.2 CHBe+ non-cirrhotic Europeans 21 -- 3.3.3 CHBe- non-cirrhotic Europeans 23 -- 3.3.4 Patient with compensated liver cirrhosis 25 -- 3.4 SCENARIO AND PROBABILISTIC SENSITIVITY ANALYSES 27 -- 3.4.1 Probabilistic sensitivity analysis 27 -- 3.4.2 ICERs in function of the time horizon 30 -- 3.4.3 Asian cohorts 31 -- 3.4.4 Variations in the discount rates 32 -- 3.5 BUDGET IMPACT 33 -- 4 DISCUSSION AND CONCLUSIONS 34 -- 5 APPENDICES 37 -- 5.1 NATURAL PROGRESSION TO LIVER CIRRHOSIS IN 278 CHRONIC HEPATITIS B -- PATIENTS OF EUROPEAN ORIGIN, THE IMPORTANCE OF AGE AND ELEVATED ALT . 37 -- 5.1.1 Introduction 37 -- 5.1.2 Aim 37 -- 5.1.3 Methods 37 -- 5.1.4 Results 38 -- 5.1.5 Discussion and Conclusion 39 -- 5.2 COMPARISON OF PUBLISHED QUALITY OF LIFE DATA 40 -- 5.2.1 Aims 40 -- 5.2.2 Methods 41 -- 5.2.3 Results 43 -- 5.3 DISEASE MANAGEMENT COSTS 46 -- 5.3.1 Data sources 48 -- 5.3.2 Primary inclusion counts 52 -- 5.3.3 Exclusions and sub grouping for cost study 53 -- 5.3.4 Extrapolations for partial lump sum remunerations 59 -- 5.3.5 Results 66 -- 5.3.6 Discussion 72 -- 6 REFERENCES 74 Link for e-copy: https://kce.fgov.be/publication/report/economic-evaluation-of-antiviral-treatmen [...] Format of e-copy: Webpage Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2584 Copies
Barcode Call number Media type Location Section Status No copy Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
![]()
Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C [printed text] / Sophie Gerkens, Author ; Nancy Thiry, Author ; Frank Hulstaert, Author ; Jo Robays, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2016 . - 144 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 276C) .
ISSN : D/2016/10.273/88 : 0,00
Study 2015-08
Languages : English (eng)
Descriptors: Indexation
2015-08 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis C ; R276
Classification
WC 536 Human viral hepatitisContents note: SCIENTIFIC REPORT 14 -- 1 INTRODUCTION .14 -- 1.1 BACKGROUND 14 -- 1.1.1 Transmission 14 -- 1.1.2 Hepatitis C in Belgium 15 -- 1.1.3 Treatments 16 -- 1.2 OBJECTIVE OF THIS REPORT AND RESEARCH QUESTIONS 17 -- 2 REVIEW OF THE PUBLISHED ECONOMIC EVALUATIONS 18 2.1 INTRODUCTION .18 -- 2.2 METHODS 18 2.2.1 Inclusion and exclusion criteria .18 -- 2.2.2 Search strategy .19 2.2.3 Selection procedure 19 2.2.4 Coverage of the reviews 21 -- 2.3 CLASSIFICATION OF THE ECONOMIC EVALUATIONS 21 -- 2.3.1 Early publications based on emerging and weak evidence 21 -- 2.3.2 Pegylated interferon as an intervention 21 -- 2.3.3 Disease progression after sustained viral response 22 -- 2.3.4 Selected economic evaluations 22 -- 2.4 OVERVIEW OF THE SELECTED ECONOMIC EVALUATIONS 23 -- 2.4.1 Country and study design 23 -- 2.4.2 Perspective .23 -- 2.4.3 Time horizon and discount rate .23 -- 2.4.4 Targeted patient group 23 -- 2.4.5 Intervention and comparators 23 -- 2.4.6 Assumptions used in modelling the HCV natural history .24 2.4.7 Non-liver mortality 25 -- 2.4.8 Quality of life 25 -- 2.5 MAIN RESULTS OF THE ECONOMIC EVALUATIONS 34 -- 2.5.1 Genotype 1 34 -- 2.5.2 Genotype 2 35 -- 2.5.3 Genotype 3 35 -- 2.5.4 Genotype 4 35 -- 2.6 SENSITIVITY AND SUBGROUP ANALYSES .35 -- 2.6.1 Sensitivity analyses .35 -- 2.6.2 Subgroup analyses .35 -- 2.7 DISCUSSION 41 -- 2.7.1 Summary of the results .41 -- 2.7.2 General conclusion .42 -- 3 THE COST-EFFECTIVENESS AND BUDGET IMPACT OF TREATMENT STRATEGIES FOR HEPATITIS C IN BELGIUM 43 -- 3.1 INTRODUCTION .43 -- 3.2 METHODS 43 -- 3.2.1 Design and analytic technique 43 -- 3.2.2 Perspective .44 -- 3.2.3 Time window and discounting 44 -- 3.2.4 Target population .44 -- 3.2.5 Intervention and comparator 45 -- 3.2.6 Model structure and basic assumptions 45 -- 3.2.7 Transition probabilities 48 -- 3.2.8 Performance of non-invasive liver tests 50 -- 3.2.9 Effectiveness of antiviral treatment .52 -- 3.2.10 Disease management, diagnostic tests and treatment costs 53 -- 3.2.11 Utilities 59 -- 3.2.12 Uncertainty 63 -- 3.2.13 Validation of the model 66 -- 3.3 RESULTS 66 -- 3.3.1 Cost-effectiveness analysis.66 -- 3.3.2 Budget impact analysis .72 -- 4 DISCUSSION AND CONCLUSION 80 -- APPPENDICES 83 -- APPENDIX 1. SCENARIO ANALYSES .83 -- APPENDIX 1.1. KCE REPORTS 157 ANTIVIRAL TREATMENT - ANNUAL TRANSITION PROBABILITIES BETWEEN FIBROSIS STAGES103 83 -- APPENDIX 1.2. TABLES OF THE SCENARIO ANALYSES FOR THE COST-EFFECTIVENESS ANALYSES 86 -- REFERENCES . 137 Link for e-copy: http://doi.org/10.57598/R276C Format of e-copy: PDF (825 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3943 Economische evaluatie van antivirale behandeling van chronische hepatitis B in België / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
Economische evaluatie van antivirale behandeling van chronische hepatitis B in België : Deel 2 [printed text] / Christoph Schwierz, Author ; Nancy Thiry, Author ; Stefaan Van de Sande, Author ; Mohamed Gamil, Author ; Frederik Nevens, Author ; Isabelle Colle, Author ; Yvres Horsmans, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - X, 77 p. : ill. ; A4. - (KCE Reports A. Health Technology Assessment (HTA); 157A) .
ISSN : D/2011/10.273/27 : 0,00
studie n° 2008-11 HTA Chronic hep B
Languages : English (eng) Dutch (nla)
Descriptors: Indexation
2008-11 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis B virus ; Hepatitis B, Chronic ; R157
Classification
WC 536 Human viral hepatitisAbstract: Sinds enkele jaren zijn nieuwe geneesmiddelen beschikbaar voor de behandeling van chronische hepatitis B. De kostprijs van deze behandeling bedraagt zowat 5000 euro per patiënt per jaar. De beleidsmakers vroegen aan het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) na te gaan welke groepen patiënten het meest baat kunnen hebben bij deze behandeling, en tegen welke prijs. Het KCE concludeerde dat het behandelen van een meer gevorderd ziektestadium, in dit geval levercirrose, gepaard gaat met de hoogste gezondheidswinst per gespendeerde euro. De berekeningen door het KCE zijn gebaseerd op een origineel onderzoek naar het ziekteverloop en de ziektekosten in samenwerking met een groot aantal leverspecialisten. Contents note: GLOSSARY 2 -- 1 BACKGROUND AND OBJECTIVES 3 -- 1.1 NATURAL HISTORY AND EPIDEMIOLOGY 3 -- 1.2 TREATMENT 4 -- 1.3 OBJECTIVES AND CONTENT OF THE TWO REPORTS 5 -- 2 METHODS 7 -- 2.1 TARGET POPULATION 7 -- 2.2 MODEL STRUCTURE AND BASIC ASSUMPTIONS 7 -- 2.3 TRANSITION PROBABILITIES 9 -- 2.4 DISEASE MANAGEMENT AND TREATMENT COSTS 12 -- 2.5 UTILITIES 13 -- 2.6 ANTIVIRAL TREATMENT 14 -- 3 RESULTS 16 -- 3.1 MODEL VALIDATION: NATURAL EVOLUTION OF DISEASE WITHIN EUROPEAN -- COHORTS 17 -- 3.2 HEALTH OUTCOMES 18 -- 3.2.1 Life-years gained in the three cohorts 18 -- 3.2.2 Undiscounted life-years gained in DC and HCC 19 -- 3.2.3 Mean tenofovir treatment duration in CHB e+ vs e- cohorts 20 -- 3.3 BASE-CASE COST-UTILITY ANALYSES 20 -- 3.3.1 Overview of the results for the three base-case cohorts 20 -- 3.3.2 CHBe+ non-cirrhotic Europeans 21 -- 3.3.3 CHBe- non-cirrhotic Europeans 23 -- 3.3.4 Patient with compensated liver cirrhosis 25 -- 3.4 SCENARIO AND PROBABILISTIC SENSITIVITY ANALYSES 27 -- 3.4.1 Probabilistic sensitivity analysis 27 -- 3.4.2 ICERs in function of the time horizon 30 -- 3.4.3 Asian cohorts 31 -- 3.4.4 Variations in the discount rates 32 -- 3.5 BUDGET IMPACT 33 -- 4 DISCUSSION AND CONCLUSIONS 34 -- 5 APPENDICES 37 -- 5.1 NATURAL PROGRESSION TO LIVER CIRRHOSIS IN 278 CHRONIC HEPATITIS B -- PATIENTS OF EUROPEAN ORIGIN, THE IMPORTANCE OF AGE AND ELEVATED ALT . 37 -- 5.1.1 Introduction 37 -- 5.1.2 Aim 37 -- 5.1.3 Methods 37 -- 5.1.4 Results 38 -- 5.1.5 Discussion and Conclusion 39 -- 5.2 COMPARISON OF PUBLISHED QUALITY OF LIFE DATA 40 -- 5.2.1 Aims 40 -- 5.2.2 Methods 41 -- 5.2.3 Results 43 -- 5.3 DISEASE MANAGEMENT COSTS 46 -- 5.3.1 Data sources 48 -- 5.3.2 Primary inclusion counts 52 -- 5.3.3 Exclusions and sub grouping for cost study 53 -- 5.3.4 Extrapolations for partial lump sum remunerations 59 -- 5.3.5 Results 66 -- 5.3.6 Discussion 72 -- 6 REFERENCES 74 Link for e-copy: http://doi.org/10.57598/R157A Format of e-copy: PDF (1,3 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2583 Copies
Barcode Call number Media type Location Section Status No copy Evaluatie van universele en doelgroep hepatitis A vaccinatie opties in België / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
![]()
PermalinkEvaluation économique du traitement antiviral de lhépatite B chronique en Belgique / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
PermalinkÉvaluation de programmes de vaccination généraux et ciblés contre lhépatite A en Belgique / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
![]()
PermalinkHépatite C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
![]()
PermalinkHépatite C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
![]()
Permalink[Hepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
![]()
PermalinkHepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
![]()
PermalinkHepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
![]()
PermalinkHepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)
![]()
PermalinkKosteneffectiviteit van antivirale behandeling voor chronische hepatitis B in België / Yvres Horsmans / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
![]()
Permalink
